Skip to main content

Table 1 GSTT2 polymorphisms and colorectal cancer risk

From: GSTT2 promoter polymorphisms and colorectal cancer risk

Locus HWE MAF Genotype Healthy controls (N = 568) CRC patients (N = 436) p OR(95% CI)
-537 0.999 0.42 GG 203 (35.7%) 127 (29.1%) 0.025 1.373 (1.041–1.810)
    GA or AA 365 (64.3%) 309 (70.9%)   
-277 0.548 0.07 TT 489 (86.1%) 388 (89.0%) 0.125 0.735 (0.495–1.090)
    TC or CC 79 (13.9%) 48 (11.0%)   
-158 0.314 0.03 GG 522 (91.9%) 416 (95.4%) 0.032 0.539 (0.307–0.947)
    GA or AA 46 (8.1%) 20 (4.6%)   
  1. Adjusted for age and sex; HWE: Hardy-Weinberg equilibrium for controls; MAF: Minor allele frequency
  2. Dominant model: Homozygote of major allele vs. heterozygote and homozygote of minor allele